We are live on ! Find out more
SPRB

Spruce Biosciences

49 hedge funds and large institutions have $14.1M invested in Spruce Biosciences in 2024 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 12

32% more funds holding

Funds holding: 3749 (+12)

0% more call options, than puts

Call options by funds: $39K | Put options by funds: $39K

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

67% less funds holding in top 10

Funds holding in top 10: 31 (-2)

85% less capital invested

Capital invested by funds: $94.4M → $14.1M (-$80.3M)

Holders
49
Holders Change
+12
Holders Change %
+32.43%
% of All Funds
0.71%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
24
Increased
7
Reduced
8
Closed
12
Calls
$39K
Puts
$39K
Net Calls
Net Calls Change

SPRB Hedge Fund Activity: Q1 2024 in Review

49 of the 6,947 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q1 2024, worth a combined $14.1M — down 85% from $94.4M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new SPRB positions and 12 closed out — a net gain of 12 holders — while 7 added to existing stakes and 8 trimmed.

The largest buyer was Altium Capital Management, opening a new position worth an estimated $3.9M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $19.7M sold.

  • 49 institutional investors held Spruce Biosciences (SPRB) as of Q1 2024, up from 37 in Q4 2023.
  • Funds reported $14.1M of Spruce Biosciences stock for Q1 2024, down 85% quarter-over-quarter.
  • 24 funds opened new Spruce Biosciences positions in Q1 2024 and 12 closed out, a net change of +12 holders.
  • The largest Spruce Biosciences buyer in Q1 2024 was Altium Capital Management, an estimated $3.9M added.
  • The largest Spruce Biosciences seller in Q1 2024 was Novo Holdings A/S, an estimated $19.7M sold.

Based on aggregated 13F filings for Q1 2024.